share_log

Pfizer | DEFA14A: Others

Pfizer | DEFA14A: Others

辉瑞 | DEFA14A:其他
美股sec公告 ·  04/11 11:04
Moomoo AI 已提取核心信息
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, according to a recent SEC filing. This filing, which is not preliminary and requires no fee, is a standard procedure for publicly traded companies in compliance with Section 14(a) of the Securities Exchange Act of 1934. The materials are intended for Pfizer's shareholders and do not constitute soliciting material. This step indicates that Pfizer is preparing for upcoming engagements with its shareholders, although the specific contents of the materials were not disclosed in the announcement.
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, according to a recent SEC filing. This filing, which is not preliminary and requires no fee, is a standard procedure for publicly traded companies in compliance with Section 14(a) of the Securities Exchange Act of 1934. The materials are intended for Pfizer's shareholders and do not constitute soliciting material. This step indicates that Pfizer is preparing for upcoming engagements with its shareholders, although the specific contents of the materials were not disclosed in the announcement.
根据美国证券交易委员会最近的一份文件,辉瑞公司已向美国证券交易委员会(SEC)提交了明确的额外材料,这是其委托声明附表14A的一部分。根据1934年《证券交易法》第14(a)条,该文件不是初步的,不收取任何费用,是上市公司的标准程序。这些材料是为辉瑞的股东准备的,不构成招标材料。这一举措表明,辉瑞正在为即将到来的与股东的交易做准备,尽管公告中没有披露这些材料的具体内容。
根据美国证券交易委员会最近的一份文件,辉瑞公司已向美国证券交易委员会(SEC)提交了明确的额外材料,这是其委托声明附表14A的一部分。根据1934年《证券交易法》第14(a)条,该文件不是初步的,不收取任何费用,是上市公司的标准程序。这些材料是为辉瑞的股东准备的,不构成招标材料。这一举措表明,辉瑞正在为即将到来的与股东的交易做准备,尽管公告中没有披露这些材料的具体内容。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息